Current and future challenges in quality assurance in molecular diagnostics.


Journal

Clinica chimica acta; international journal of clinical chemistry
ISSN: 1873-3492
Titre abrégé: Clin Chim Acta
Pays: Netherlands
ID NLM: 1302422

Informations de publication

Date de publication:
Aug 2021
Historique:
received: 30 10 2020
revised: 04 05 2021
accepted: 05 05 2021
pubmed: 11 5 2021
medline: 22 6 2021
entrez: 10 5 2021
Statut: ppublish

Résumé

The development and performance of molecular genetic assays has required increasingly complex quality assurance in recent years and continues to pose new challenges. Quality management officers, as well as academic and technical personnel are confronted with new molecular genetic parameters, methods, changing regulatory environments, questions regarding appropriate validation, and quality control for these innovative assays that are increasingly applying quantification and/or multiplex formats. Yet, quality assurance and quality control guidelines are still not widely available or in some circumstances have become outdated. For these reasons, the need for solutions to provide test confidence continues to grow. In order to integrate new test procedures into existing quality assurance measures, the ISO 15189 guideline can serve as an orientation. The ISO 15189 guideline describes requirements for medical laboratories and thus includes those performing molecular diagnostics. This article gives an overview of the possibilities and challenges in quality assurance of molecular parameters and shows possible solutions.

Identifiants

pubmed: 33971158
pii: S0009-8981(21)00153-4
doi: 10.1016/j.cca.2021.05.004
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

239-246

Informations de copyright

Copyright © 2021 Elsevier B.V. All rights reserved.

Auteurs

Parviz Ahmad-Nejad (P)

Institute for Medicine Laboratory Diagnostics, Centre for Clinical and Translational Research (CCTR), HELIOS University Hospital, Wuppertal, Witten/Herdecke University, Germany. Electronic address: parviz.ahmad-nejad@helios-gesundheit.de.

Tester Ashavaid (T)

Department of Laboratory Medicine, P.D. Hinduja National Hospital and Medical Research Center, Mumbai, India.

Aldo Vacaflores Salinas (A)

Plexus Laboratorio, La Paz, Bolivia.

Jim Huggett (J)

National Measurement Laboratory (NML) at LGC, Queens Rd, Teddington, TW11 0LY, United Kingdom; School of Biosciences & Medicine, Faculty of Health & Medical Science, University of Surrey, Guildford GU2 7XH, United Kingdom.

Kathryn Harris (K)

Microbiology Department, Great Ormond Street Hospital NHS Foundation Trust, London, UK.

Mark W Linder (MW)

Department of Pathology and Laboratory Medicine, University of Louisville School of Medicine, Louisville, KY, USA.

Katarina Baluchova (K)

OncoLab Diagnostics GmbH Technologie- und Forschungszentrum, Viktor-Kaplan-Straße 2, 2700 Wiener Neustadt, Austria.

Werner Steimer (W)

Institute for Clinical Chemistry and Pathobiochemistry, Munich University of Technology, Klinikum rechts der Isar, D-81675 Munich, Germany.

Deborah A Payne (DA)

CPDP Consulting, LLC, Denver, CO, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH